QLT kept at sector perform by RBC

RBC Capital Markets analyst Douglas Miehm maintained QLT Inc. at sector perform, above average risk, following the company's analyst day. Novartis AG announced Visudyne sales of $75.1 million, a 39.3% decrease from the previous year. As a result, QLT lowered its guidance for 2006 to $340 million to $355 million from sales of $370 million to $380 million. QLT's presentations indicated that the future of AMD treatment will be combination therapies, according to the analyst. Shares of the Vancouver, B.C.-based biopharmaceutical company were up 15 cents, or 1.85%, at $8.26. (Nasdaq: QLTI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.